Inactive Instrument

Highlights Affymax, Inc. Nasdaq

Equities

US00826A1097

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014	Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer	CI
2014	Affymax Seeks Acquisitions	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Affymax Seeks Acquisitions	14-11-26	CI
Affymax, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014	14-07-31	CI
Affymax Terminates Omontys' Product Collaboration and License Agreement with Takeda Pharmaceutical Company, Effective September 10, 2014	14-06-16	CI
Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement	14-06-13	CI
Affymax, Inc. Executes a Seventh Amendment to Lease Agreement	13-08-20	CI
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection	13-02-25	CI
Affymax, Inc. and Takeda Pharmaceuticals Announces Pivotal Phase 3 Data on the Safety and Efficacy of OMONTYS(R) (peginesatide) Injection	13-01-23	CI
Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. Announces Analyze from OMONTYS(R) (Peginesatide) Injection Phase 3 Dialysis Studies	12-11-01	CI
Takeda Pharmaceuticals U.S.A., Inc. and Affymax Announce Supply Agreement for OMONTYS (peginesatide) Injection with U.S. Renal Care	12-08-08	CI
Takeda Pharmaceuticals U.S.A., Inc. and Affymax, Inc. Announce Supply Agreement for OMONTYS (Peginesatide) Injection with Fresenius Medical Care North America	12-07-12	CI
Affymax, Inc. Enters into a Co-Promotion Agreement with Takeda Pharmaceuticals	12-02-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer